Chantix (varenicline): Label Change - Risk of Certain Cardiovascular Adverse Events
[UPDATED 07/22/2011] FDA has approved an updated drug label for Chantix (varenicline) to include information about the efficacy and safety of the drug in two patient populations who may benefit greatly from giving up smoking—those with... (Source: Drugs.com - Pharma News)

Smoking Cessation Drug Chantix (varenicline) May Lead To Increased Risk Of Cardiovascular Serious Adverse Events
Varenicline, a drug launched in 2006 after receiving marketing approval from the US Food and Drug Administration, which is widely used to help smokers to quit smoking, increases the risk of serious cardiovascular adverse events by 72%, states an article in CMAJ (Canadian Medical Association Journal). The risks of serious cardiovascular illness and death are often motivating reasons for people to quit smoking, and they resort to drugs such as varenicline... (Source: Health News from Medical News Today)